GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...

Vaccine sales faced challenges due to external pressures in the U.S. and China, impacting Arexvy and Shingrix. The introduction of the Inflation Reduction Act is expected to have a GBP150 million to ...

36,405 people played the daily Crossword recently. Can you solve it faster than others?36,405 people played the daily Crossword recently. Can you solve it faster than others? Billionaire Investor ...

Vaccine sales reflects the challenges we've seen from external pressures in the U.S. and China for Arexvy and Shingrix. Going forward, we expect these to continue in 2025, but equally remain ...

Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while sales for its respiratory syncytial virus (RSV) vaccine Arexvy dropped by 51%. CEO Emma Walmsley acknowledged the ...

Vaccines sales declined 3% in 2024, reflecting pressures on Arexvy and Shingrix in the U.S. However, Arexvy remains the market leader, and international uptake is gaining momentum. Emily Field ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Explore the key data from our strong 2024 performance. Operating profits dropped ...

Meanwhile, vaccine sales slipped by 4% for the year, driven by a sharp drop for its Arexvy lung disease treatment. Operating profits dropped by 40% to £4 billion due to a £1.8 billion settlement ...

General medicines grew 6%, with Trelegy sales up 27%. However, vaccine revenue fell 4%, as Arexvy sales dropped 51%. Despite strong growth, total operating profit declined 33% due to a £1.8 ...